Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus

Lupus

Volumn 18, Issue 11, 2009, Pages 980-989

  Petri, M ^a   Singh, S ^a   Tesfasyone, H ^a   Dedrick, R ^b   Fry, K ^b   Lal, P G ^b   Williams, G ^b   Bauer, J W ^c   Gregersen, P K ^d   Behrens, T W ^e   Baechler, E C ^c  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b XDx Inc   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^e GENENTECH INC   (United States)

Author keywords

Gene expression; Longitudinal analysis; Systemic lupus erythematosus; Type I interferon

Indexed keywords

INTERFERON;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE I; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICROARRAY ANALYSIS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 70349505809     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309105529     Document Type: Article

References (43)

1. Kotzin BL. Systemic lupus erythematosus. Cell 1996; 85: 303-306.
2. Jacobi AM, Diamond B. Balancing diversity and tolerance: Lessons from patients with systemic lupus erythematosus. J Exp Med 2005; 202: 341-344.
3. Lipsky PE. Systemic lupus erythematosus: An autoimmune disease of B cell hyperactivity. Nat Immunol 2001; 2: 764-766.
4. Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med 1979; 301: 5-8.
5. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610-2615.
6. Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-723.
7. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52: 1491-1503.
8. Nikpour M, Dempsey AA, Urowitz MB, Gladman DD, Barnes DA. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythematosus. Ann Rheum Dis 2007; 67: 1069-1087.
9. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006; 54: 1906-1916.
10. Bauer JW, Baechler EC, Petri M, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006; 3: E491.
11. Savarese E, Chae OW, Trowitzsch S, et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 2006; 107: 3229-3234.
12. Vallin H, Blomberg S, Alm GV, Cederblad B, Ronnblom L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin Exp Immunol 1999; 115: 196-202.
13. Baechler EC, Gregersen PK, Behrens TW. The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 2004; 16: 801-807.
14. Schmidt KN, Ouyang W. Targeting interferon-alpha: A promising approach for systemic lupus erythematosus therapy. Lupus 2004; 13: 348-352.
15. Graham RR, Kozyrev SV, Baechler EC, et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38: 550-555.
16. Graham RR, Kyogoku C, Sigurdsson S, et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A 2007; 104: 6758-6763.
17. Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 2003; 36: 511-518.
18. MacDermott EJ, Cherian J, Santiago AG, et al. Type 1 interferon pathway activation predicts flares of disease activity in SLE. Arthritis Rheum 2008; 58: 3974-3975.
19. Landolt-Marticorena C, Bonventi G, Lubovich A, et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 2008.
20. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007; 8: 492-502.
21. Petri M. Hopkins Lupus Cohort. 1999 update. Rheum Dis Clin North Am 2000; 26: 199-213v.
22. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550-2558.
23. Symmons DP, Coppock JS, Bacon PA, et al.; Members of the British Isles Lupus Assessment Group (BILAG). Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Q J Med 1988; 69: 927-937.
24. Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol 2000; 27: 377-379.
25. Han GM, Chen SL, Shen N, et al. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun 2003; 4: 177-186.
26. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
27. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
28. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003; 19: 185-193.
29. Kirou KA, Lee C, George S, et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3958-3967.
30. Feng X, Wu H, Grossman JM, et al. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2951-2962.
31. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998; 95: 15623-15628.
32. Indraccolo S, Pfeffer U, Minuzzo S, et al. Identification of genes selectively regulated by IFNs in endothelial cells. J Immunol 2007; 178: 1122-1135.
33. Rasmussen UB, Wolf C, Mattei MG, et al. Identification of a new interferon-alpha-inducible gene (p27) on human chromosome 14q32 and its expression in breast carcinoma. Cancer Res 1993; 53: 4096-4101.
34. Ravirajan CT, Rowse L, MacGowan JR, Isenberg DA. An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: A cross-sectional study. Rheumatology (Oxford) 2001; 40: 1405-1412.
35. Shi L, Reid LH, Jones WD, et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006; 24: 1151-1161.
36. Kariuki SN, Crow MK, Niewold TB. The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. Arthritis Rheum 2008; 58: 2818-2823.
37. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 2008; 58: 2481-2487.
38. Whitney AR, Diehn M, Popper SJ, et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A 2003; 100: 1896-1901.
39. Mandl JN, Barry AP, Vanderford TH, et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med 2008; 14: 1077-1087.
40. Cobb JP, Mindrinos MN, Miller-Graziano C, et al. Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci U S A 2005; 102: 4801-4806.
41. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001; 14: 461-470.
42. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003; 19: 225-234.
43. Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999; 189: 521-530.